Michael Poch
Overview
Explore the profile of Michael Poch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, et al.
J Urol
. 2024 May;
212(1):74-86.
PMID: 38704840
Purpose: Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector-based gene therapy for bacillus Calmette-Guérin (BCG)-unresponsive carcinoma in situ (CIS) with/without high-grade Ta/T1. We report outcomes following 5 years of planned follow-up....
2.
Bazargan S, Bunch B, Ojwang A, Blauvelt J, Landin A, Ali J, et al.
Front Immunol
. 2023 Oct;
14():1275375.
PMID: 37901214
Background: New therapeutics in development for bladder cancer need to address the recalcitrant nature of the disease. Intravesical adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) can potentially induce...
3.
Murthy P, Naidu S, Davaro F, Spiess P, Zemp L, Poch M, et al.
Curr Oncol
. 2023 Mar;
30(3):3223-3231.
PMID: 36975458
Introduction And Objective: Muscle invasive bladder cancer with extravesical extension is an aggressive disease entity that requires multimodal therapy. The benefits of adjuvant chemotherapy (AC) in patients with a positive...
4.
Kumar N, Bahl S, Dhillon J, Poch M, Manley B, Li R, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831597
Clinical trials play a critical role in evidence-based medicine, when rigorous scientific methodology is utilized to discover and test the effectiveness and safety of new drugs to prevent or cure...
5.
Awasthi S, Grass G, Torres-Roca J, Johnstone P, Pow-Sang J, Dhillon J, et al.
J Natl Cancer Inst
. 2022 Sep;
114(12):1656-1664.
PMID: 36053178
Background: Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the performance of genomic classifiers to risk classify African...
6.
Kumar N, Hogue S, Pow-Sang J, Poch M, Manley B, Li R, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36010981
Accumulating evidence supports green tea catechins (GTCs) in chemoprevention for prostate cancer (PCa), a leading cause of cancer morbidity and mortality among men. GTCs include (-)-epigallocatechin-3-gallate, which may modulate the...
7.
Alkhouli M, Bazargan S, Pilon-Thomas S, Poch M, Chahoud J
Cancer J
. 2022 Jul;
28(4):294-300.
PMID: 35880939
Genitourinary (GU) cancers have greatly benefited from immunotherapy treatments, such as immune checkpoint inhibitors. However, the durable clinical response rate for these agents remains relatively low, calling for more innovative...
8.
Fink A, DeRenzis A, Awasthi S, Jahan N, Johnstone P, Pow-Sang J, et al.
Cancer Med
. 2022 Jul;
12(2):1869-1877.
PMID: 35796421
Participation in cancer research trials by minority populations is imperative in reducing disparities in clinical outcomes. Even with increased awareness of the importance of minority patient inclusion in clinical research...
9.
Youssef I, Poch M, Raghunand N, Pow-Sang J, Johnstone P
Can J Urol
. 2022 Feb;
29(1):10976-10978.
PMID: 35150217
Introduction: To evaluate the use of preoperative magnetic resonance imaging (MRI) as a predictor of positive margins after radical prostatectomy (RP). This is important as such patients may benefit from...
10.
Mitra A, Narayan V, Mokkapati S, Miest T, Boorjian S, Alemozaffar M, et al.
Eur Urol
. 2021 Dec;
81(3):223-228.
PMID: 34933753
A recent phase 3 trial of intravesical nadofaragene firadenovec reported a promising complete response rate for patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. This study examined the ability of antiadenovirus...